20 results about "Retina cell" patented technology

The invention discloses a multiband LED epitaxial structure and a preparation method thereof, and relates to the technical field of semiconductors. A multi-quantum well light-emitting layer of the multiband LED epitaxial structure comprises a first long-wave blue light multi-quantum well light-emitting layer, a second medium-wave blue light multi-quantum well light-emitting layer, a third short-wave blue light multi-quantum well light-emitting layer and a fourth short-wave blue light end quantum well light-emitting layer which are sequentially stacked. The LED chip manufactured through the epitaxial structure can emit light of three different wave bands including long-wave blue light, medium-wave blue light and short-wave blue light, the excitation light source with the blue light of the three wave bands excites the red-green mixed fluorescent powder layer, a full-spectrum white light LED light source can be generated, and compared with a blue light LED chip with only one wave band, the full-spectrum white light LED light source has the advantages that the light emitting efficiency is improved, and the light emitting efficiency is improved. The ratio of short-wave blue light below 450 nm is small, damage to human eye retina cells is small, and a healthy full-spectrum white light LED light source with a high color rendering index can be achieved.

The utility model relates to the technical field of lenses, in particular to a spherical lens and cylindrical lens double-control fusion lens, which comprises a lens body and is characterized in that the lens body comprises a base layer I, and an anti-reflection layer, an ultraviolet-proof layer, an impact-resistant layer, a photochromic layer and a stain-resistant layer are arranged on the surface of the lens body. An anti-reflection layer is fixedly adhered to one side of the base layer I through a resin adhesive, and an ultraviolet-proof layer is adhered to the other side of the anti-reflection layer through the resin adhesive. According to the scheme, the functionality is remarkably improved through the multi-layer composite structure design (the anti-reflection layer, the ultraviolet-proof layer, the anti-impact layer and the like), in addition, the micro lenses of the first base layer and the second base layer are distributed in a staggered mode by rotating by 30 degrees, the one-person two-mirror alternate wearing mechanism (alternating every 2-4 weeks) is combined, fatigue of retina cells caused by fixed stimulation is avoided through dynamic out-of-focus stimulation, and the anti-fatigue performance of the retina cells is improved. Meanwhile, alternate recovery is promoted, so that myopia development is intervened more scientifically.

Provided herein are compositions including peptides, pharmaceutical preparations thereof, and methods of preventing photoreceptor death therewith and protecting retina cells, including, but not limited to, photoreceptors and retinal pigment epithelium, from Fas- or TRAIL-mediated apoptosis.

The application discloses a method for constructing a RP mouse model caused by Prpf6 gene mutation and haploinsufficiency and application thereof, and belongs to the field of molecular biology and biomedical technology. The mouse model constructed by the method provides a convenient, reliable and economical means for studying the relationship between the PRPF6 gene mutation and the retinal pigment degeneration disease and the pathogenic mechanism thereof, and provides a stable hereditary effective research model in the research of the pathogenic mechanism, treatment method and drug screening of RP. The animal model is subjected to transcriptome and a series of type detection, wherein the transcriptome result shows that the retina of the Prpf6 gene knockout mouse has a certain degree of metabolic abnormality, and the results of the electro-physiological detection, fundus examination and H&E staining show that the cell layer of the mouse retina and the shape and function of the retina are damaged, which is consistent with the disease phenotype of RP.

The present application relates to the technical field of retinal ischemia-reperfusion injury, and specifically to RNA, pharmaceutical compositions, conjugates and applications. The nucleotide sequence of the RNA is shown in SEQ ID NO: 1 and / or SEQ ID NO: 2. The RNA can inhibit the proliferation of retinal Müller cells, increase the changes in mitochondrial membrane potential of retinal Müller cells, promote Müller cell apoptosis, reduce Müller cell glial activation and protect ganglion cells from damage, reduce the inflammatory response of retinal ischemia-reperfusion injury, and has application prospects in the prevention and treatment of retinal ischemia-reperfusion injury.

Disclosed are adeno-associated virus (AAV) capsid protein variants that have improved infectivity and transduction efficiency for target cells, and uses thereof. Specifically, the disclosure relates to AAV2 variant capsid proteins selected by directed evolution for gene delivery to retinal cells, recombinant AAV vectors comprising the same, and uses thereof as gene delivery vehicles to retinal cells.

The invention relates to the technical field of nursing materials, and discloses eye washing liquid for relieving eye fatigue and a preparation method thereof.The eye washing liquid is prepared from trehalose, taurine, sodium gualenate, sodium hyaluronate, ergothioneine, vitamin B12, vitamin B6, xanthophyll, mint, a humectant, a bacteriostatic agent, a chelating agent, a pH regulator and deionized water. Through the synergistic effect of the first synergistic composition and the second synergistic composition, retina cell injury induced by blue light can be effectively repaired, the repairing effect is superior to that of simple addition of a single component, blue light oxidative injury is repaired through a multi-target synergistic mechanism, a three-layer structure of a tear film lipid layer, a water layer and a mucoprotein layer can be reconstructed, and the repairing effect is good. According to the present invention, the tearable film stability is significantly improved, the excellent protection and repair effect is provided, the compatibility of the components is good, the product stability is high, and the multiple effects of ocular surface cleaning, asthenopia relieving, conjunctival congestion reducing and blue light oxidation damage preventing are provided.

This invention discloses a gene therapy method targeting USP8 for the treatment of retinal degenerative diseases and its application. The study found that USP8 expression is downregulated in aging and retinal degenerative disease mouse models; knockout... Usp8 Mice exhibiting retinal degeneration showed signs of retinal degeneration, and overexpression of USP8 was able to rescue these lesions. This finding indicates that USP8 plays a crucial role in maintaining retinal cell homeostasis and delaying retinal degeneration. Regulating USP8 expression levels can significantly improve retinal function, providing a novel potential target and strategy for the treatment of retinal degenerative diseases.

The present disclosure relates to pharmaceutical compositions comprising a lipid nanoparticle (LNP), a therapeutic nucleic acid (TNA) and at least one pharmaceutically acceptable excipient, wherein the LNP comprises at least one lipid, and wherein the LNP is capable of delivering the TNA to a retinal cell. Methods of treating ocular diseases and disorders are also provided.

The invention relates to the technical field of lighting equipment, in particular to a negative oxygen ion eye-protection lamp capable of inhibiting myopia and relieving asthenopia, which comprises an eye-protection lamp body, a lamp post and a negative oxygen ion generator, the eye-protection lamp body is used for emitting full-spectrum light; the negative oxygen ion generator is installed at the joint of the eye protection lamp body and the lamp pole, and the concentration of negative oxygen ions generated by the negative oxygen ion generator is 5000-5000 / cm < 3 >. When the eye protection lamp is used, the negative oxygen ion generator is arranged at the joint of the eye protection lamp body and the lamp pole, the negative oxygen ion generator can generate negative oxygen ions with the concentration of 5000-50000 / cm < 3 >, more dopamine is secreted by a living body through the negative oxygen ions, the fundus blood flow density and the fundus retina cell activity are improved, the choroid thickness is increased, and therefore the eye protection effect is improved. Therefore, the visual comfort is improved, and the effects of inhibiting myopia and relieving asthenopia are achieved.

The invention provides a product with an eye protection function, and belongs to the technical field of eye health. The invention provides application of components of aronia melanocarpa fruits in preparation of eye protection products. The aronia melanocarpa fruit extract is found to have a protection effect on eye cell apoptosis, retinal injury and the like, for example, the aronia melanocarpa fruit extract has an eye protection effect of resisting eye blue light injury, remarkably improves retina cell apoptosis caused by illumination and meanwhile reduces the in-vivo lipid peroxidation level and the in-vivo inflammation level. Based on the eye protection effect of the aronia melanocarpa fruit extract, the invention develops drugs for preventing and treating retinal light injury diseases and relieving disease symptoms, develops health-care foods with functions of relieving visual fatigue and the like, and also develops common foods containing the aronia melanocarpa fruits.

The present disclosure relates to the technical field of biomedicine, and in particular to use of miRNA or modified miRNA in treating fundus oculi diseases. The miRNA or modified miRNA has biological activity, can be absorbed by cells in vitro or retina cells in vivo, and quickly plays a biological role. Through a topical administration mode, the miRNA or the modified miRNA can inhibit pathological neovascularization, promote recovery of a non-perfusion region, reduce expression of retinal inflammatory factors, relieve retinal fibrosis, and promote nerve injury repair. The method has very good application and research values in the field of biomedicine.

The application discloses a multi-waveband LED epitaxial structure and a preparation method thereof, and relates to the technical field of semiconductors. The multi-waveband LED epitaxial structure is characterized in that the multi-quantum well light-emitting layer comprises a first long-wave blue light multi-quantum well light-emitting layer, a second middle-wave blue light multi-quantum well light-emitting layer, a third short-wave blue light multi-quantum well light-emitting layer and a fourth short-wave blue light multi-quantum well light-emitting layer which are stacked in sequence. The LED chip prepared by using the epitaxial structure can emit three different wavebands of long-wave blue light, middle-wave blue light and short-wave blue light. The excitation light source with the three wavebands of blue light can excite a red-green mixed fluorescent powder layer to generate a full-spectrum white light LED light source. Compared with the blue light LED chip with only one waveband, the short-wave blue light with a wavelength of less than 450 nm accounts for a small proportion, the damage to the human eye retina cells is small, and the healthy full-spectrum white light LED light source with a high color rendering index can be realized.

The invention discloses a gene therapy method for treating retina degenerative diseases by targeting USP8 and application of the gene therapy method. The research finds that the USP8 expression in an aging and retinal degeneration mouse model is down-regulated; the mouse with Usp8 knockout has retinal degeneration, and the retinal degeneration can be rescued through USP8 overexpression. The discovery shows that the USP8 plays a key role in maintaining the steady state of retinal cells and delaying the retinal degeneration process. By regulating and controlling the expression level of the USP8, the retina function can be remarkably improved, and a new potential target and strategy are provided for treatment of retinal degenerative diseases.

The invention provides an LED light source for protecting retina cells of human eyes, the luminescent spectrum of the LED light source is a continuous spectrum of 380-800nm, the LED light source does not contain ultraviolet light which is less than 380nm and is harmful to the human eyes, and the luminous intensity of the spectrum at the wavelength of 750-800nm is maximum. Compared with the prior art, the LED light source provided by the invention can effectively protect human eye retinal pigment epithelial cells while providing good illumination efficiency, and the LED light source is economical, durable, energy-saving, environment-friendly and suitable for large-scale popularization.

The general inventive concepts contemplate methods and compositions for modifying certain cell lines to facilitate the production of retinal tissue from human induced pluripotent stem cells. Human induced pluripotent stem cells can be cultured to develop into retinal organoids, among other cells types. The retinal organoids play a role in modeling both human retinal development and retinal disease. The methods and compositions discussed herein provide means to measure and monitor human induced pluripotent stem cells during development.

The present invention provides a production method of a retinal cell or retinal tissue, including the following steps:(1) a first step of culturing mammalian pluripotent stem cells in the absence of a feeder cell for a period not exceeding 30 days in a medium comprising 1) a factor for maintaining an undifferentiated state and 2) an MEK inhibitor,(2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and(3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.

The present invention relates to: a compound of chemical formula 1; a pharmaceutical composition comprising same as an active ingredient; and a use thereof. The compound of chemical formula 1 according to the present invention may exhibit inhibitory activity against cell necrosis and ferroptosis in various cells such as heart cells, kidney cells, nerve cells, retina cells, liver cells, or lung cells, and thus can be effectively used for preventing or treating cell diseases related to cell necrosis or ferroptosis.

The invention relates to the technical field of lighting equipment, in particular to an eye protection lamp capable of inhibiting myopia and relieving fatigue, which comprises a shell and a negative ion generator, a substrate, a light source module and a light guide plate are sequentially arranged in an inner cavity of the shell from inside to outside, and the light source module is provided with a blue light bead group, a purple light bead group and a dark red light bead group. The wavelength of a light source emitted by the light source module ranges from 385 nm to 780 nm, the wavelength of a light source emitted by the purple light lamp bead set ranges from 385 nm to 420 nm, and the wavelength of a light source emitted by the dark red light lamp bead set ranges from 650 nm to 780 nm. During use, the ultraviolet lamp bead group with the light source wavelength of 385-420 nm and the dark red lamp bead group with the light source wavelength of 650-780 nm are arranged in the light source module and are matched with the negative ion generator for use, so that organisms are promoted to secrete more dopamine, the fundus blood flow density and the fundus retina cell activity are improved, the choroid thickness is increased, and the growth of the ocular axis is inhibited; the vision comfort is improved, myopia is inhibited, the blood oxygen concentration is increased, free radicals in the body are eliminated, and fatigue is relieved.